These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 15016325)
41. Antigenic Hsp70-peptide upregulate altered cell surface MHC class I expression in TAMs and increases anti-tumor function in Dalton's lymphoma bearing mice. Gautam PK; Acharya A Tumour Biol; 2015 Mar; 36(3):2023-32. PubMed ID: 25431260 [TBL] [Abstract][Full Text] [Related]
42. HSP70L1-mediated intracellular priming of dendritic cell vaccination induces more potent CTL response against cancer. Liu S; Yi L; Ling M; Jiang J; Song L; Liu J; Cao X Cell Mol Immunol; 2018 Feb; 15(2):135-145. PubMed ID: 27345726 [TBL] [Abstract][Full Text] [Related]
43. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. Arnold D; Faath S; Rammensee H; Schild H J Exp Med; 1995 Sep; 182(3):885-9. PubMed ID: 7650492 [TBL] [Abstract][Full Text] [Related]
44. Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Suzue K; Zhou X; Eisen HN; Young RA Proc Natl Acad Sci U S A; 1997 Nov; 94(24):13146-51. PubMed ID: 9371814 [TBL] [Abstract][Full Text] [Related]
45. Increased expression of HSP70 by colon cancer cells is not always associated with access to the dendritic cell cross-presentation pathway. Matera L; Forno S; Galetto A; Moro F; Garetto S; Mussa A Cell Mol Biol Lett; 2007; 12(2):268-79. PubMed ID: 17235439 [TBL] [Abstract][Full Text] [Related]
46. Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Brossart P; Bevan MJ Blood; 1997 Aug; 90(4):1594-9. PubMed ID: 9269778 [TBL] [Abstract][Full Text] [Related]
47. Heat shock protein derived from a non-autologous tumour can be used as an anti-tumour vaccine. Casey DG; Lysaght J; James T; Bateman A; Melcher AA; Todryk SM Immunology; 2003 Sep; 110(1):105-11. PubMed ID: 12941147 [TBL] [Abstract][Full Text] [Related]
48. Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70. Moroi Y; Mayhew M; Trcka J; Hoe MH; Takechi Y; Hartl FU; Rothman JE; Houghton AN Proc Natl Acad Sci U S A; 2000 Mar; 97(7):3485-90. PubMed ID: 10725409 [TBL] [Abstract][Full Text] [Related]
49. Enhanced generation of cytotoxic T lymphocytes by heat shock protein 70 fusion proteins harboring both CD8(+) T cell and CD4(+) T cell epitopes. Takemoto S; Nishikawa M; Guan X; Ohno Y; Yata T; Takakura Y Mol Pharm; 2010 Oct; 7(5):1715-23. PubMed ID: 20695521 [TBL] [Abstract][Full Text] [Related]
50. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation. Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164 [TBL] [Abstract][Full Text] [Related]
51. Heat shock proteins transfer peptides during antigen processing and CTL priming. Srivastava PK; Udono H; Blachere NE; Li Z Immunogenetics; 1994; 39(2):93-8. PubMed ID: 8276462 [TBL] [Abstract][Full Text] [Related]
52. Mycobacterium tuberculosis heat shock fusion protein enhances class I MHC cross-processing and -presentation by B lymphocytes. Tobian AA; Harding CV; Canaday DH J Immunol; 2005 May; 174(9):5209-14. PubMed ID: 15843516 [TBL] [Abstract][Full Text] [Related]
53. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. Paglia P; Chiodoni C; Rodolfo M; Colombo MP J Exp Med; 1996 Jan; 183(1):317-22. PubMed ID: 8551239 [TBL] [Abstract][Full Text] [Related]
54. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. den Haan JM; Lehar SM; Bevan MJ J Exp Med; 2000 Dec; 192(12):1685-96. PubMed ID: 11120766 [TBL] [Abstract][Full Text] [Related]
55. Tumor-specific CD4+ T cells are activated by "cross-dressed" dendritic cells presenting peptide-MHC class II complexes acquired from cell-based cancer vaccines. Dolan BP; Gibbs KD; Ostrand-Rosenberg S J Immunol; 2006 Feb; 176(3):1447-55. PubMed ID: 16424172 [TBL] [Abstract][Full Text] [Related]
57. Anti-tumor vaccination in heterozygous congenic F1 mice: presentation of tumor-associated antigen by the two parental class I alleles. Carmon L; Tzehoval E; Tirosh B; el-Shami KM; Bar-Haim E; Vadai E; Feldman M; Eisenbach L J Immunother; 2000; 23(3):344-52. PubMed ID: 10838663 [TBL] [Abstract][Full Text] [Related]
58. Immunotherapy with dendritic cells pulsed with tumor-derived gp96 against murine lung cancer is effective through immune response of CD8+ cytotoxic T lymphocytes and natural killer cells. Shinagawa N; Yamazaki K; Tamura Y; Imai A; Kikuchi E; Yokouchi H; Hommura F; Oizumi S; Nishimura M Cancer Immunol Immunother; 2008 Feb; 57(2):165-74. PubMed ID: 17628800 [TBL] [Abstract][Full Text] [Related]